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Down syndrome (DS) is associated with neurological complications, including cognitive deficits that lead to impairment in intellectual
functioning. IncreasedGABA-mediated inhibition has been proposed as amechanismunderlying deficient cognition in the Ts65Dn (TS)
mousemodelofDS.WeshowthatchronictreatmentofthesemicewithRO4938581(3-bromo-10-(difluoromethyl)-9H-benzofimidazo[1,
5-a][1,2,4]triazolo[1,5-d][1,4]diazepine), a selective GABAA 5 negative allosteric modulator (NAM), rescued their deficits in spatial
learning and memory, hippocampal synaptic plasticity, and adult neurogenesis. We also show that RO4938581 normalized the high
density of GABAergic synapse markers in the molecular layer of the hippocampus of TS mice. In addition, RO4938581 treatment sup-
pressed thehyperactivity observed inTSmicewithout inducinganxietyoraltering theirmotorabilities.Thesedatademonstrate that reducing
GABAergic inhibition with RO4938581 can reverse functional and neuromorphological deficits of TS mice by facilitating brain plasticity and
support the potential therapeutic use of selective GABAA5NAMs to treat cognitive dysfunction inDS.
Introduction
Down syndrome (DS) is the most common genetic cause of in-
tellectual disability (Bittles et al., 2007). The disorder is caused by
trisomy of chromosome 21 and is associated with neurological
complications, including cognitive deficits that lead to impair-
ment in intellectual functioning (Lott andDierssen, 2010). There
is currently no pharmacological therapeutic option available for
the treatment of cognitive deficits in people with DS.
The genetic dependence of the cognitive phenotype in DS has
been recapitulated inmousemodels of the condition ofwhich the
Ts65Dn (TS)mouse is themostwidely used (Kahlemet al., 2004).
This murine model shows several fundamental features of DS,
including learning and memory deficits (Escorihuela et al., 1995;
Reeves et al., 1995; Holtzman et al., 1996) with alterations in both
hippocampal morphology (Insausti et al., 1998; Kurt et al., 2004)
and adult neurogenesis (Rueda et al., 2005; Clark et al., 2006;
Llorens-Martín et al., 2010).
Excessive GABA-mediated neurotransmission has been pro-
posed as one of the underlying causes of the cognitive deficits in
TSmice (Belichenko et al., 2004; Fernandez et al., 2007). TSmice
display fewer asymmetric synapses that mediate excitatory trans-
mission in the temporal cortex and dentate gyrus (DG) (Kurt et
al., 2000, 2004) and synaptic structural abnormalities in the hip-
pocampus and cortex, including a selective reorganization of the
inhibitory input (Belichenko et al., 2004; Pe´rez-Cremades et al.,
2010). In addition, enhanced GABA-mediated inhibition was as-
sociated with deficient synaptic plasticity in the hippocampus of
TS mice through a marked reduction in long-term potentiation
(LTP) in theCA1 andDGareas (Siarey et al., 1997; Kleschevnikov
et al., 2004; Costa and Grybko, 2005; Fernandez et al., 2007).
Furthermore, overexpression of Olig1 and Olig2, two genes trip-
licated in DS and TS mice, are linked to the neurogenesis defects
that led to an imbalance between excitatory and inhibitory neu-
rons and to increased inhibitory drive in the TS forebrain
(Chakrabarti et al., 2010). In line with these findings, previous
studies showed that reducing inhibitory neurotransmission by
chronic administration of nonselective GABAA receptor antago-
nists reversed the deficits in LTP and hippocampal-mediated
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memoryofTSmice (Fernandez et al., 2007; Rueda et al., 2008a).How-
ever,nonselectiveGABAA receptor antagonists are anxiogenic andpro-
convulsant (Dorow et al., 1983; Little et al., 1984).
Among the different GABAA receptor subtypes, GABAA 5
subunit-containing receptors are preferentially localized in the
hippocampus and play a key modulatory role in cognition
(Collinson et al., 2002; Crestani et al., 2002; Rudolph and Knoflach,
2011). Moreover, selective GABAA 5 negative allosteric modu-
lators (NAMs), also called inverse agonists, have cognition-
enhancing effects without anxiogenic or proconvulsant side
effects (Collinson et al., 2006; Dawson et al., 2006; Nutt et al.,
2007; Ballard et al., 2009). Here we show that RO4938581 (3-
bromo-10-(difluoromethyl)-9H-benzofimidazo[1,5-a][1,2,4]
triazolo[1,5-d][1,4]diazepine), a selective GABAA 5 NAM, can
reverse concomitantly electrophysiological, neuromorphologi-
cal, and cognitive deficits of TS mice.
Materials andMethods
Animals
This study was approved by the Cantabria University Institutional Lab-
oratory Animal Care and Use Committee and performed in accordance
with the Declaration of Helsinki and the European Communities Council
Directive (86/609/EEC). For experiments performed at F. Hoffmann-La
Roche, the experimental procedures received previous approval from the
City of Basel Cantonal Animal Protection Committee based on adher-
ence to federal and local regulations on animal maintenance and testing.
TS mice were generated by repeated backcrossing of B6EiC3Sn a/A-
Ts(1716)65Dn females with C57BL/6Ei  C3H/HeSNJ (B6EiCSn)
F1 hybrid males. The parental generation was provided by the Robertso-
nian ChromosomeResources (The Jackson Laboratory), andmating was
performed at the animal facilities of the University of Cantabria. In all
experiments, TS mice were compared with euploid littermates (CO). To
determine the presence of the trisomy, animals were karyotyped using
real-time quantitative PCR as described previously (Liu et al., 2003).
Because C3H/HeSnJ mice carry a recessive mutation that leads to retinal
degeneration, all animals were genotyped by standard PCR to screen out
all mice carrying this gene.
Mice were housed in groups of two or three in clear Plexiglas cages
(20 22 20 cm) in standard laboratory conditions with a temperature
of 22  2°C, 12 h light/dark cycle, and access to food and water ad
libitum. Light/dark cycle was inverted so that behavioral studies were
conducted during the active period of the mice.
In this study, four cohorts ofmalemice were used. The first cohort was
used to determine the effect of RO4938581 on cognition, sensorimotor
abilities, and neuromorphology in TS and CO mice, the second cohort
was used to test the effects of this compound on anxiety and LTP, the
third cohort was used to assess whether or not RO4938581 had a convul-
sant effect, and the fourth cohort was used for additional LTP studies. All
mice were 3–4 months old at the beginning of the treatment. Mice from
cohorts one and two received RO4938581 for 6 weeks before the behav-
ioral assessment and for the subsequent behavioral evaluation.
In the first cohort, 10 CO and 10 TS mice received RO4938581; the
other two groups of CO (n 13) and TS (n 13) mice received vehicle.
In the second cohort, 10 animals per group received RO4938581 or ve-
hicle, and in the third and fourth cohorts, RO4938581 was administered
to eight TS and eight CO mice.
Pharmacological treatment
RO4938581 (F. Hoffmann-La Roche) was dissolved in chocolate milk
(Puleva) and administered to the mice by voluntary drinking. Before
pharmacological treatment, TS and CO mice were conditioned to drink
chocolatemilk in a clean standard cage from small Petri dishes for 1week.
During the 6 first weeks of drug administration, the mice were intro-
duced individually in clean cages containing a small Petri dish containing
either chocolate milk alone (vehicle) or RO4938581 dissolved in choco-
late milk (drug) at the same time of the day (10:00 A.M.). Mice drank all
the drug or vehicle within 5 min and then were returned to their home
cages. The dose of 20 mg/kg RO4938581 in 150 l of chocolate milk was
chosen because it led to plasma concentrations that correlated with 50–
70% GABAA 5 receptor occupancy under these conditions. During the
behavioral assessment, drug was made available 1 h before testing; all
mice regularly consumed the entire chocolate milk–drug mixture. For
the study of potential convulsant activity of RO4938581 in TS mice, the
compound was prepared in 0.3% Tween 80 v/v 0.9% saline with 100 ml
of H2O and administered orally by gavage (50 mg/kg) to achieve higher
plasma and brain exposures.
Behavioral studies
The experimenters were blind to genotype and pharmacological treat-
ment throughout the entire behavioral assessment. Mice from cohort
one were used for behavioral testing (actimetry, sensorimotor testing,
rotarod, and hole board tests). To decrease the chances of behavioral
responses being altered by previous test history, the most invasive pro-
cedures were performed last. Studies were performed in the following
order: actimetry, sensorimotor testing, rotarod, open field, and hole
board. For cohort two, mice were assessed in the plus maze.
Spatial learning and memory: Morris water maze
To evaluate spatial learning and memory, a modified version of the Morris
watermazewas used. The apparatus was a circular tank 110 cm in diameter,
full of water (22–24°C) made opaque by the addition of powdered milk.
Inside the tank, a platformwas hidden 1 cm below the water level.
Mice were studied at the end of the drug treatment period in 16 con-
secutive daily sessions: 12 acquisition sessions (platform submerged),
followed by a probe trial and four cued sessions (platform visible) (Fig.
1a). All trials were videotaped with a camera located 2m above the water
level. The Anymaze computerized tracking system (Stoelting) was used
to analyze the mouse trajectories and measure escape latency, distance
traveled, swimming speed, and thigmotaxis for each animal in each trial.
We chose this watermaze protocol because it allows better observation
of the learning deficits of TS mice and, therefore, is more suitable for
assessing the efficacy of pharmacological intervention (Stasko andCosta,
2004; Rueda et al., 2008a, b).
Training sessions. In the acquisition sessions (S1–S12), the platform
was hidden 1 cm below water level. During the first eight sessions, the
platform position was changed every day to assess trial-dependent learn-
ing (i.e., spatial working memory). In this protocol, the ability of the
animal to find the platform relies only on stochastic search strategy and
not an integration of knowledge ormemory during the testing or training
phases. In sessions 9–12, the platform was placed in the same location
(SW) (standard protocol) to assess trial-independent spatial learning.
Each of the 12 acquisition and the cued sessions (one session per day)
consisted of four pairs of trials, 30–45 min apart. For each trial pair, the
mice were randomly started from one of four positions (north, south,
east, west), which was held constant for both trials. The first trial of a pair
was terminated when the mouse located the platform or when 60 s had
elapsed; the second trial commenced after a period of 20 s, during which
the mouse was allowed to stay on the platform. Several fixed visual cues
outside of the maze were constantly visible from the pool.
Probe trial. After the last acquisition session, a probe trial was per-
formed to evaluate memory of the platform position (spatial memory).
During this trial, the platformwas removed from the tank. In a single 60 s
trial, the number of times that the mice crossed over the place where the
platform was located during the acquisition trials, the number of entries
in the trained quadrant, and the percentage of time spent in each of the
quadrants was recorded.
Cued session. During the cued sessions, the platform was visible: the
water level was 1 cm below the platform, and its position was indicated
with a flag. Eight trials were performed during each session, following the
same experimental procedure as in the acquisition sessions.
Motor tests
Motor coordination and reflex test battery
A battery of motor tests was performed following the procedure de-
scribed by Rueda et al. (2008b). In the visual placing reflex test, cerebellar
and vestibular functions were evaluated. In three consecutive trials, mice
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were gently lowered by the tail toward a flat surface from a height of 15
cm. The response of forepaw extension was scored on a 0–4 scale: 4,
animal extends the forepaws when placed at the highest height; 3, fore-
paws extended before touching the surface with vibrissae; 2, forepaws
extended after vibrissae touched the surface; 1, forepaws extended after
the nose touched the surface; 0, no extension.
To evaluate auditory sensitivity, the startle response to a sudden audi-
tory stimulus was measured. Mice were placed facing the wall of an
unfamiliar cage, and the auditory stimulus was generated by clapping
together two stainless steel forceps (7 cm long). A score (0–3 points) was
assigned based on the magnitude of the response: 3 points, jumping1
cm; 2 points, jumping 1 cm; 1 point, retracting of the ears (Preyer
reflex); 0 points, no response.
The vibrissa placing reflex was analyzed by noting the reflective
reaction to touching the vibrissae with a cotton stick. In three con-
secutive trials, a score of 1 was assigned to animals that touched the
Figure 1. RO4938581 improved spatial learningandmemoryof TSmice.a, Schematic drawingof theMorriswater-maze test design. Chronic treatmentwithRO4938581 improvedperformanceof TSmice
in theacquisitionandprobe sessionsof theMorriswatermaze. In addition, RO4938581 treatment reduced thigmotactic behavior in TSandCOmice.DataarepresentedasmeansSEMof the latency to reach
theplatformduring the12acquisition (b) andcued(d) sessions, thepercentageof timespent in theperipheryof themazeduring theacquisitionsessions (c), thepercentageof time in the fourquadrantsduring
theprobe trial (e), thenumberof entries in the trainedquadrant (f ), and thenumberof crossingsover theplatformposition (g) by the fourgroupsofmice. *p0.05, **p0.01, ***p0.001, TSversusCO;
#p 0.05, ##p 0.01, ###p 0.001, vehicle versus RO4938581, Bonferroni’s tests after significant ANOVAS (RM-ANOVAs; for statistics, see Table 3).
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stimulated vibrissae with an ipsilateral paw and 0 if there was no
response.
Grip strength was assessed by quantifying the resistance to being sep-
arated from a lid of aluminum bars (2 mm), when dragged by the tail: 0,
no resistance, total loss of grip strength; 1, slight; 2, moderate; 3, active; 4,
extremely active resistance, normal grip strength.
To evaluate equilibrium, four 20 s trials of balance were performed on
an elevated (40 cmhigh), horizontal (50 cm long) rod. Trials 1 and 2were
performed on a flat wooden rod (9 mm wide); trials 3 and 4 were per-
formed on a cylindrical aluminum rod (1 cm diameter). In each trial, the
animals were placed in a marked central zone (10 cm) on the elevated
rod. A score of 0 was given if the animal fell within 20 s, 1 if it stayed
within the central zone for 20 s, 2 if it left the central zone, and 3 if it
reached one of the ends of the bar.
Prehensile reflex (three 5 s trials) was measured as the ability of the
animal to remain suspended by the forepaws by grasping an elevated
horizontal wire (2 mm in diameter). The maximum possible score of 3
was achievedwhen the animal remained suspended by the forepaws in all
three trials (1 point per trial). Traction capacity was scored at the same
time by assessing the number of hindlimbs that the animal raised to reach
the wire: 0, none; 1, one limb; 2, two limbs.
Motor coordination: rotarod
Motor coordination was evaluated using a rotarod device (Ugo Basile)
that consisted of a 37 cm long, 3 cm diameter plastic rod that rotates at
different speeds. In a single session, four trials with amaximumduration
of 60 s each were performed. In the first three tests, the rod was rotated at
constant speeds of 5, 25, and 50 rpm, respectively. The last trial consisted
of an acceleration cycle, in which the rod rotated progressively faster, and
the animal had to adapt to the growing demands of the test. The length of
time that each animal stayed on the rotarod during the acceleration cycle
was recorded.
Spontaneous activity: actimetry
In this test, the circadian variation of the animals’ spontaneous locomo-
tor activity during a complete light/dark cycle of 24 h was evaluated. The
apparatus is a device (Acti-System II; Panlab) that detects the changes
produced in amagnetic field by themovement of themice. It registers the
movements of animals during a continuous 24 h cycle (12 h of light and
12 h of darkness).
Anxiety
Open field
Exploratory behavior and anxiety were assessed using a square-shaped
open field (55 55 cm, surrounded by a 25-cm-tall fence), divided into
25 equal squares. The mice were placed in the center of the field, and the
number of vertical (rearing) activities and horizontal crossings (from
square to square, subdivided into center vs peripheral crossings) were
scored in a single 5 min trial.
Plus maze
The elevated plus maze consisted of two closed arms (5  30 cm, with
clear perplex walls 15 cm high) and two open arms (5 cm wide 30 cm
long) raised 40 cm from the floor. In a single 5 min trial, the mice were
placed in the center of themaze, and the number of arm entries, the time
spent in open and closed arms, and number of stretch attend postures
(SAPs) and head dippings (HDs) were registered. Entries to the open
arms and time spent and distance traveled in these arms are exploratory
behaviors negatively correlated with anxiety. The number of SAPs and
HDs constitutes the degree of risk assessment performed by mice and
cognitive components of anxiety (Rodgers and Johnson, 1995). The trials
were videotaped, and both the distance traveled by each mouse in open
and closed arms and the speed in each trial were measured with the
computerized tracking system Anymaze.
Exploratory activity: hole board
The hole board is a wooden box (32 32 30 cm) with four holes. The
floor is divided into nine 10 cm squares. In a single 5 min trial, the
number of explorations, the time spent exploring each hole, and overall
activity in the apparatus were measured. A repetition index was also
calculated (exploration of holes explored previously) as a function of the
number of A–B–A alternations.
Assessment of possible seizure activity
Potential convulsant effect of RO4938581 at concentrations above effi-
cacious plasma levels was assessed after a single gavage administration of
50 mg/kg of the compound. Eachmouse was placed in a transparent box
with sawdust bedding in which it could be observed, and the proportion
of mice that exhibited tonic convulsions was recorded for 1 h.
In vivo binding of RO4938581 to GABAA 5 receptors
Tritiated RO0154513 (Ethyl 8-azido-5,6-dihydro-5-methyl-6-oxo-4H-
imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate) was synthesized in
the isotope laboratory of F.Hoffmann-LaRochewith a specific activity of
52 Ci/mmol. Male TS and CO mice (body weights, 20–37 g) were used
for the in vivo binding experiments. RO4938581 was dissolved in choc-
olate milk and administered orally at a concentration of 20 mg/kg in a
volume of 150 l. Three COmice and two TS mice were pretreated with
RO4938581 and 60 min later intravenously received 0.1 mCi/kg
[ 3H]RO0154513 (equivalent to a dose of 0.6g/kg). Mice were killed by
decapitation 15 min after administration of the radioligand. Brains and
blood were collected from each mouse. Blood was collected in heparin–
lithium tubes (Milian), and all samples were submitted to the Roche
analytical laboratories for the determination of RO4938581 exposure.
Brains were rapidly removed, divided in two halves along their sagittal
axis, and frozen in dry ice. Half brain was submitted to the Roche ana-
lytical laboratories for the determination of the brain concentrations of
RO4938581. The other half was placed in a cryostat, and sagittal sections
(10m thickness) were cut (four sections per brain). Brain sections were
mounted on Histobond glass slides (Marienfeld Laboratories Glass-
ware), dried at room temperature, and exposed, together with tritium
microscales, to tritium-sensitive imaging plates (BAS-TR2025) for 5 d.
The imaging plates were scanned in a Fujifilm BAS-5000 high-resolution
phosphor imager, and the amount of [ 3H]RO0154513 bound to the
brain regions of interest was quantified with anMCIDM2 image analysis
system (Imaging Research) and expressed as femtomoles of
[ 3H]RO0154513 per milligram of protein. Inhibition of radioligand
binding by RO4938581 in the hippocampus of TS and CO mice was
estimated by using the hippocampus/cerebellum ratio as an indication of
specific binding. The cerebellum was chosen as a reference region for
nonspecific [ 3H]RO0154513 binding because this region is almost de-
void of GABAA 5 receptors (Fritschy and Mohler, 1995). The recep-
tor blockade (or occupancy) in the hippocampus produced by
RO4938581 was calculated according to the following equation: %
blockade  (1  (Hi/Ce ratiodrug/Hi/Ce ratiovehicle))  100.
LTP
Mice were decapitated 1 h after the last oral administration, and the
brains were rapidly removed. The hippocampi were dissected, and 400
m slices were cut with a tissue chopper. Slices were allowed to recover
for at least 1 h in an interface chamber at room temperaturewith artificial
CSF containing the following (in mM): 120 NaCl, 3.5 KCl, 2.5 CaCl2, 1.3
MgSO4, 1.25 NaH2PO4, 26 NaHCO3, and 10 D-glucose (saturated with
95%O2 and 5%CO2). Field EPSPs (fEPSPs)were recorded from theCA1
stratum radiatum with a glass micropipette (1–4 M	) containing 2 M
NaCl and evoked by stimulation of the Schaffer collaterals with insulated
bipolar platinum/iridium electrodes500 m away from the recording
electrode. The stimulus strength was adjusted to evoke fEPSPs equal to
50% of the relative maximum amplitude without superimposed popula-
tion spike. After stable baseline recordings (100 s pulse duration, 0.033
Hz), LTP was induced by theta burst stimulation (10 trains of five pulses
at 100Hz and intervals of 200ms). The duration of the stimulation pulses
was doubled during the tetanus. fEPSPswere amplified, bandpass filtered
(1 Hz to 1 kHz), and stored in a computer using the Spike 2 program
(Cambridge Electronic Design). For the analysis, fEPSP slopes were ex-
pressed as a percentage of the baseline values recorded. Results from
several slices were expressed as mean  SEM. The statistical analysis
was performed by repeated-measures (RM) multivariate ANOVA
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(MANOVA) (time treatment genotype). All the analyses were done
using SPSS for Windows version 18.0.
Histological and stereological procedures
Micewere deeply anesthetizedwith pentobarbital and transcardially per-
fused with saline, followed by 4% paraformaldehyde. After being re-
moved and postfixed in 4% paraformaldehyde overnight at 4°C and
transferred into 30% sucrose, the brains were frozen in dry ice and sliced
coronally in a cryostat (50-m-thick sections). Series of brain slices were
randomly made up of one section of every eight for the immunohisto-
chemistry protocol.
Granule cell count
One-in-eight series of sections was selected at random and 4
6-
diamidino-2-phenylindole (DAPI) stained; for this purpose, mature
granule cells in the hippocampal granule cell layer (GCL) were counted
in sections stained with DAPI (1:1000;Calbiochem) for 10 min in phos-
phate buffer (PB) (0.1 M). Cell counts were measured using a previously
described physical dissector system coupled to confocal microscopy
(Llorens-Martín et al., 2006). Random numbers were generated to select
the points where to locate the dissectors. Six dissectors in each section
were measured. In the selected points, the confocal microscope was di-
rected toward a position previously established randomly inside the
granule layer. Next, in each point, a series of 11 confocal images was
serially recorded keeping to the general rules of the physical dissector and
the unbiased stereology. The confocal images were then analyzed by the
computer with the aid of NIH ImageJ software (version 1.33; http://rsb.
info.nih.gov/ij). Every successive pair of images was used, considering
one of them the reference image and the other the sample image. Next,
the sample image becomes the reference image of the next pair of images,
and so on. The cells were counted with NIH ImageJ Cell Counter, label-
ing in the screen cell by cell the first time they appear in the series of
confocal images. The software generates the total number of cells when
the dissector brick is completed. For counting the mature granule neu-
rons in the GCL, the dissector frame was a square situated randomly
inside the GCL. The number of cells is then referred to the reference
volume of the dissector (this parameter is the volume of a prism formed
by the area of the frame multiplied by the height of the dissector), to
obtain a number of cells per volume unit (cell density).
Cell proliferation in the subgranular zone of the DG
(Ki67 immunofluorescence)
Slices were initially preincubated in PB with 1% Triton X-100 and 1%
bovine serum albumin (BSA), and then dual immunohistochemistry was
performed as described previously (Llorens-Martín et al., 2006). Briefly,
free-floating slices were incubated with primary antibody rabbit anti-
Ki67 (1:750; Abcam) diluted in PBwith 1%TritonX-100 and 1%BSA for
2 d at 4°C. Then slices were incubated overnight at 4°C with secondary
antibody Alexa Fluor 594-conjugated donkey anti-rabbit IgG (1:1000;
Invitrogen). The sections were counterstained with DAPI and mounted
in gelatin-covered slides to be analyzed and photographed. The total
number of Ki67-positive cells were counted with the help of an optical
fluorescence microscope (Leica DMI 6000 B, oil-immersion 40 objec-
tive) using the optical dissector method described previously (Llorens-
Martín et al., 2006).
Density of GABAergic synapse markers (glutamate decarboxylases
65 and 67, vesicular GABA transporter, and gephyrin
immunofluorescence)
Three dedicated sets of 1-in-8 series of 50 m sections of mouse
brains were used for the determination of GABAergic boutons.
GABAergic synapses in the hippocampus were identified by immu-
nocytochemistry with three GABAergic synapse markers mouse anti-
glutamate decarboxylase 65 (GAD65, 1:500; Millipore Bioscience
Research Reagents), followed by Alexa Fluor 594-conjugated donkey
anti-mouse Ig (1:1000; Invitrogen), rabbit anti-glutamate decarbox-
ylase 67 (GAD67, 1:200; Abcam), and rabbit anti-vesicular GABA
transporter (VGAT, 1:200; Millipore Bioscience Research Reagents),
followed by Alexa Fluor 488 donkey anti-rabbit Ig (1:1000; Invitro-
gen). To study colocalization of VGATwith the postsynaptic scaffold-
ing proteinmarker gephyrin, slices were submitted to double-labeling
immunohistochemistry anti-VGAT (1:200; Millipore Bioscience Re-
search Reagents), followed by Alexa Fluor 488 donkey anti-rabbit Ig
(1:1000; Invitrogen) and anti-gephyrin (1:200; Synaptic Systems),
followed by Alexa Fluor 594-conjugated donkey anti-mouse Ig (1:
1000; Invitrogen). Measurements were performed in images recorded
with a confocal microscope (Leica TCS 4D), using a 63 oil objective
and a 9 zoom. For each synapse marker, four sections per animal
were used comprising the entire hippocampus, and one random area
in the hippocampus per section was measured. Image analysis was
performed with the aid of NIH ImageJ software (version 1.33;
http://rsb.info.nih.gov/ij). Briefly, boutons with positive immunoflu-
orescence (GAD65, GAD67, VGAT, or gephyrin) were measured sep-
arately applying the same threshold to all pictures. Images were
previously converted to grayscale to improve the contrast between
signal and noise. Areas were measured inside a reference circle with a
standard size of 325 m2. Reference space was located in the inner
molecular layer of the hippocampal DG, lining the most external layer
of granule neurons in the GCL. The percentage of reference area
occupied by GAD65-, GAD67-, VGAT-, gephyrin-, and VGAT/
gephyrin-positive boutons was calculated.
Statistical analyses
The water maze data of the acquisition sessions (S1–S8 and S9–S12) and
thigmotactic behavior were analyzed using a two-way RM-ANOVA (ses-
sion genotype treatment or trial genotype treatment). LTPdata
were analyzed by RM-MANOVA (time  treatment  genotype). The
rest of the behavioral and neuromorphological data were analyzed using
two-way (genotype  treatment) ANOVAs. The means of each experi-
mental group were compared post hoc by Student’s t test if two groups
were compared or Bonferroni’s tests if more than two groups were com-
pared. All the analyses were done using SPSS for Windows version 18.0.
The F values of RM-ANOVAs, two-way ANOVAs, and post hoc analysis
of each independent variable tested in the Morris water maze, LTP, hole
board, sensorimotor abilities, open field, and plusmaze and are shown in
Tables 1–5, respectively.
Table 1. Hole-board data (mean scores SEM)
Vehicle RO4938581 F(1,43)
CO TS CO TS Genotype Treatment Genotype treatment
Crossings (n) 79.00 5.24 127.15 11.86*** 73.27 8.31 106.11 9.80* 18.98, p 0.001 2.07, p 0.057 0.67, p 0.41
Rearings (n) 11.54 1.98 13.77 2.55 17.73 3.06 20.67 5.69 0.63, p 0.43 4.05, p 0.051 0.01, p 0.91
Number of HDs 18.15 1.84 22.62 2.21 14.82 2.00 18.22 1.96 3.63, p 0.063 3.51, p 0.068 0.06, p 0.79
Time exploring holes (s) 33.92 6.63 37.88 7.55 30.43 6.83 26.28 4.17 0.00, p 0.98 1.21, p 0.27 0.35, p 0.55
Time exploring holes with objects (s) 18.98 4.72 19.74 5.09 14.99 2.92 14.91 3.13 0.00, p 0.93 1.00, p 0.32 0.00, p 0.92
Time exploring holes without
object (s)
14.92 2.77 17.99 3.13 15.44 5.18 11.39 1.94 0.02, p 0.88 0.73, p 0.39 1.00, p 0.32
A–B–A index (n of repetitions of
recently explored holes)
3.23 0.53 5.23 0.60* 2.64 0.86 3.89 0.72 5.72, p 0.021 2.02, p 0.16 0.30, p 0.58
A–B–A/number of HDs 0.17 0.02 0.24 0.02* 0.15 0.03 0.21 0.02 5.011, p 0.031 0.57, p 0.45 0.04, p 0.84
*p 0.05; ***p 0.001, TS versus CO.
Martínez-Cue´ et al. • Enhancement of Brain Plasticity in Ts65Dn Mice J. Neurosci., February 27, 2013 • 33(9):3953–3966 • 3957
Table 3. F values of RM-MANOVAs and post hoc analysis of each independent variable tested in the acquisition and cued sessions of the Morris water maze
Session Genotype Treatment Genotype treatment
Acquisition between sessions (S1–S8)
RM-MANOVA genotype treatment F(7,38) 18.71, p 0.001 F(1,38) 26.91, p 0.001 F(1,38) 10.68, p 0.002 F(1,38) 10.83, p 0.002
Post hoc comparisons between each pair of learning curves
Vehicle CO versus vehicle TS F(1,23) 46.14, p 0.001
RO4938581 CO versus RO4938581 TS F(1,18) 1.49, p 0.24
Vehicle TS versus RO4938581 TS F(1,23) 31.33, p 0.001
Vehicle CO versus RO4938581 CO F(1,22) 0.00, p 0.98
Acquisition (S9–S12)
RM-MANOVA genotype treatment F(3,38) 11.56, p 0.002 F(1,38) 16.24, p 0.001 F(1,38) 6.11, p 0.020 F(1,38) 8.19, p 0.008
Post hoc comparisons between each pair of learning curves
Vehicle CO versus vehicle TS F(1,23) 15.04, p 0.002
RO4938581 CO versus RO4938581 TS F(1,18) 1.98, p 0.18
Vehicle TS versus RO4938581 TS F(1,23) 7.65, p 0.018
Vehicle CO versus RO4938581 CO F(1,22) 0.16, p 0.69
Acquisition between trials
RM-MANOVA genotype trial Trial: F(7,38) 6.04, p 0.001 F(1,42) 35.62, p 0.001 F(1,38) 14.59, p 0.001 F 14.78, p 0.001
Post hoc comparisons between each pair of learning curves
Vehicle CO versus vehicle TS F(1,23) 50.67, p 0.001
RO4938581 CO versus RO4938581 TS F(1,18) 2.28, p 0.14
Vehicle TS versus RO4938581 TS F(1,23) 49.42, p 0.001
Vehicle CO versus RO4938581 CO F(1,22) 0.00, p 0.99
Thigmotaxis
(All sessions) RM-MANOVA genotype treatment F(11,38) 13.92, p 0.001 F(1,38) 20.73, p 0.001 F(1,38) 7.82, p 0.009 F(1,38) 1.89, p 0.18
S1–S12 post hoc comparisons RM-MANOVA session group
TS vehicle: F(11,9) 1.09, p 0.37
CO vehicle: F(11,9) 6.43, p 0.001
TS RO4938581: F(11,12) 5.62, p 0.001
CO RO4938581: F(11,12) 10.09, p 0.001
Mean of cued sessions MANOVA genotype treatment F(1,38) 9.82, p 0.004 F(1,38) 2.43, p 0.13 F(1,38) 2.14, p 0.15
Probe trial
n of crossings over platform
MANOVA genotype treatment F(1,38) 9.27, p 0.005 F(1,38) 1.21, p 0.29 F(1,38) 0.43, p 0.51
n of entries in trained quadrant
MANOVA genotype treatment F(1,38) 10.41, p 0.003 F(1,38) 5.24, p 0.030 F(1,38) 0.69, p 0.41
Percentage of time in quadrants
MANOVA quadrant genotype treatment Quadrant: F(3,37) 13.56, p 0.001 F(1,38) 2.91, p 0.021 F(1,38) 10.92, p 0.002 F(1,38) 1.10, p 0.30
Cues sessions
Latency
MANOVA genotype treatment:treatment F(1,38) 3.93, p 0.054 F(1,38) 8.58, p 0.006 F(1,38) 5.76, p 0.021
Speed
MANOVA genotype treatment F(1,38) 2.77, p 0.10 F(1,38) 0.55, p 0.46 F(1,38) 0.011, p 0.91
Table 2. Sensorimotor test battery, rotarod, and actimetry (mean scores SEM)
Vehicle RO4938581 F(1,43)
CO TS CO TS Genotype Treatment Genotype treatment
Vision (score 0–4 3 trials) 8.54 0.57 8.23 0.60 7.64 0.47 7.67 0.88 0.07, p 0.79 1.18 p 0.28 0.09, p 0.75
Auditory startle (score 0–3) 1.31 0.24 1.15 0.19 1.00 0.13 1.33 0.17 0.22, p 0.63 0.12, p 0.72 1.38, p 0.24
Righting reflex (score 0–3) 3.00 0.00 3.00 0.00 3.00 0.00 3.00 0.00
Grip strength (score 0–3) 2.00 0.28 1.62 0.24 1.55 0.21 2.00 0.24 0.00, p 0.92 0.00, p 0.92 3.71, p 0.061
Latency to fall wooden bar (s) 19.8 0.19 20.0 0.0 20.00 0.00 20.00 0.00 0.75, p 0.38 0.75, p 0.38 0.75, p 0.38
Equilibrium aluminum bar
(score 1–3) 1.38 0.43 2.31 0.54 1.36 0.45 1.00 0.44 0.18, p 0.67 1.48, p 0.23 1.38, p 0.24
Latency to fall aluminum bar (s) 14.03 1.42 15.11 1.55 14.73 1.28 12.11 2.07 0.37, p 0.54 0.35, p 0.55 1.05, p 0.31
Prehensile reflex (score 0–3) 2.69 0.17 2.92 0.83 2.45 0.31 2.67 0.24 1.05, p 0.31 1.31, p 0.25 0.00, p 0.97
Traction capacity (score 0–3) 2.31 0.63 2.67 0.62 1.82 0.55 1.67 0.62 0.02, p 0.86 1.43, p 0.23 0.16, p 0.68
Number of crossings coat hanging 3.62 0.96 3.67 0.34 2.64 0.43 3.33 0.50 1.46, p 0.23 2.56, p 0.11 1.29, p 0.26
Latency arrival coat hanging (s) 36.00 5.62 32.42 6.16 46.45 5.79 35.44 5.76 1.54, p 0.22 1.28, p 0.26 0.39, p 0.53
Rotarod (latency to fall, s)
5 rpm 60.00 0.00 60.00 0.00 60.00 0.00 60.00 0.00
25 rpm 30.38 5.85 39.92 6.42 35.63 7.47 34.33 6.87 0.37, p 0.54 0.00, p 0.98 0.65, p 0.42
50 rpm 11.53 3.67 11.76 4.24 16.27 3.99 10.22 3.79 0.51, p 0.47 1.55, p 0.69 0.60, p 0.44
Acceleration cycle 126.53 15.55 158.38 19.73 146.0 17.56 145.55 29.50 0.59, p 0.44 0.02, p 0.87 0.63, p 0.43
Actimetry (counts)
Dark 107030.7 18863.97 90334 4202.28 90334.4 21059.53 85212.86 10008.14 1.16, p 0.28 0.28, p 0.59 0.83, p 0.36
Light 19014.79 4144.34 17850.61 4202.28 21653.61 2096.76 7732.37 2048.73 0.52, p 0.47 0.34, p 0.56 0.07, p 0.78
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Results
RO4938581 improved cognition and rescued deficient
hippocampal LTP in TS mice
We reported previously that RO4938581 has cognition-
enhancing effects in rat andmonkey (Ballard et al., 2009). To test
whether RO4938581, through inhibition of theGABAA5 recep-
tor activity, could improve cognition in TSmice, we used amod-
ified version of theMorris watermaze task (Morris et al., 1982) as
illustrated in Figure 1a. This method allows assessment of work-
ing memory (S1–S8, trial-dependent learning), spatial learning
(S9–S12, trial-independent learning), andmemory (probe trail),
all of which are dependent on hippocampal function, followed by
four cued trials. Consistent with previous studies, TS mice
showed a pronounced learning deficit in the water maze, both
during the acquisition sessions in which the platform was placed
in different positions and those in which the platform position
was kept constant (p 0.001; Fig. 1a,b). The difference between
TS and CO mice learning curves was significantly reduced after
chronic treatment with RO4938581 in S1–S8 (p 0.24; Fig. 1b)
and S9–S12 (p  0.21; Fig. 1b). RO4938581 treatment signifi-
cantly improved the performance of TS mice during the acquisi-
tion sessions (S1–S8, p  0.001; S9–S12, p  0.005 Fig. 1b) and
had no effect onCOmice performance (S1–S8, p 0.98; S9–S12,
p 0.91; Fig. 1b). During the cued sessions (Fig. 1d), RO4938581
treatment also reduced the latency to reach the platform by TS
mice (p 0.006). In addition, RO4938581 significantly reduced
thigmotactic behavior in TS and CO mice (Fig. 1c) because
RO4938581-treated TS and COmice spent significantly less time
swimming in the periphery of the maze throughout the acquisi-
tion and cued sessions than the corresponding vehicle-treated
mice (Fig. 1c). The post hoc analysis of each of the thigmotactic
behavior curves revealed that RO4938581-treated TS and CO
mice as well as vehicle-treated CO mice significantly reduced
thigmotactic behavior throughout the sessions (p  0.001). In
contrast, vehicle-treated TSmice did not reduce the time spent in
the periphery of the pool throughout the sessions (p 0.37).
When the performance of the different group of mice was
analyzed within sessions (i.e., the latency to reach the platform in
each trial across the eight sessions), statistical analysis revealed
that vehicle-treated TSmice did not learn to localize the platform
position (p 0.59; data not shown) but that all the other groups
of mice reduced the latency to reach the platform throughout the
trials across sessions (p 0.006), i.e., they learned in each session
the new platform position.
During the probe trial, vehicle-treated TS mice showed im-
paired spatial memory because they did not show any preference
for the trained quadrant (i.e., they spent 25% of the time in
each of the quadrants; Fig. 1e), had fewer crossings over the place
where the platform was located during the acquisition trials (Fig.
1g), and entered fewer times in the trained quadrant (Fig. 1f). In
contrast, RO4938581-treated TS mice spent significantly more
time in the trained quadrant (Fig. 1e), entered significantly more
times in this quadrant (Fig. 1f), and crossed more times over the
platform position compared with vehicle-treatedmice (although
this later effect did not reach statistical significance; Fig. 1g), in-
dicating that RO4938581 improved the spatial memory impair-
ment of TS mice.
No significant differences were found in the swimming speed
of the four groups of mice (data not shown; ANOVA, genotype,
F(1,43)  0.10; treatment, F(1,43)  0.55, p  0.46; genotype 
treatment, F(1,43) 0.01, p 0.91). Mean plasma concentrations
of RO4938581 determined in a subset of TS and CO animals
during chronic treatment were 1815 and 1117 ng/ml, respec-
tively. These plasma concentrations correlate to 50% GABAA
5 receptor occupancy (see in vivo binding results).
To assess the effect of RO4938581 chronic treatment on the
hippocampal synaptic transmission and plasticity, we recorded
fEPSPs from hippocampal slices of CO and TS mice that were
chronically treated with vehicle or RO4938581. A theta burst
stimulus was used to induce LTP at the Schaffer collateral–CA1
pathway. No significant differences were found in fEPSP ampli-
tudes in the baseline of the four groups ofmice (Table 4). Vehicle-
Table 4. F values of RM-MANOVA and post hoc analysis of potentiation curves for LTP results
Genotype Treatment Genotype treatment
Basal F(1,38) 0.0.18, p 0.66 F(1,38) 0.12, p 0.72 F(1,38) 0.05, p 0.81
After theta burst stimulation
All groups, MANOVA genotype treatment F(1,38) 0.9.93, p 0.003 F(1,38) 14.38, p 0.001 F(1,38) 2.65, p 0.11
Post hoc comparisons between each pair of potentiation curves
Vehicle CO versus vehicle TS F(1,21) 16.05, p 0.001
RO4938581 CO versus RO4938581 TS F(1,17) 0.83, p 0.37
Vehicle TS versus RO4938581 TS F(1,20) 37.73, p 0.001
Vehicle CO versus RO4938581 CO F(1,18) 1.34, p 0.26
Vehicle CO versus RO4938581 TS F(1,19) 0.19, p 0.66
Table 5. F values of MANOVA (genotype treatment) for each dependent variable in the open field and plus maze
Genotype Treatment Genotype treatment
Open field
Crossings periphery F(1,43) 10.51, p 0.002 F(1,43) 0.29, p 0.58 F(1,43) 2.05, p 0.15
Crossings center F(1,43) 2.6, p 0.11 F(1,43) 4.25, p 0.045 F(1,43) 0.14, p 0.71
Total crossings F(1,43) 12.19, p 0.001 F(1,43) 1.67, p 0.02 F(1,43) 1.98, p 0.16
Rearings F(1,43) 1.63, p 2.08 F(1,43) 2.89, p 0.096 F(1,43) 1.97, p 0.16
Plus maze
n of entries open arms F(1,37) 8.33, p 0.007 F(1,37) 1.20, p 0.28 F(1,37)4.32, p 0.045
n of entries closed arms F(1,37) 4.96, p 0.033 F(1,37) 2.04, p 0.15, F(1,37) 0.24, p 0.62
Total n of entries F(1,37) 9.13, p 0.005 F(1,37) 3.60, p 0.066 F(1,37) 1.34, p 0.25
Initial freezing F(1,37) 0.55, p 0.46 F(1,37) 1.94, p 0.17 F(1,37) 0.04, p 0.83
Percentage of time in open arms F(1,37) 0.00, p 0.97 F(1,37) 0.00, p 0.93 F(1,37) 0.00, p 0.94
Risk assessment (SAP HD) F(1,37) 0.07, p 0.78 F(1,37) 6.36, p 0.017 F(1,37) 0.00, p 0.99
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treated TS mice presented deficits in LTP
relative to vehicle-treated CO mice (p 
0.001; Fig. 2). In TS mice, RO4938581
treatment produced a marked enhance-
ment of LTP relative to vehicle treatment
(p 0.001; Fig. 2). Therewas a trend (p
0.26) for RO4938581 chronic treatment
to facilitate LTP in CO mice (Fig. 2). The
amount of LTP measured in RO4938581-
treated TS mice was not different from
that of vehicle-treatedCOmice (p 0.66;
Fig. 2). Subsequently, no differences were
found between the LTP of RO4938581-
treated TS and COmice (p 0.37 Fig. 2).
The relative potentiations at 80 min after
tetanuswere 165 9%(n 11 slices from
11 different mice), 128  4% (n  12
slices from 12 different mice), 173 16%
(n  9 slices from 9 different mice), and
163 12% (n 10 slices from 10 differ-
ent mice) in vehicle-treated CO and TS
and RO4938581-treated CO and TSmice,
respectively. These findings confirm the
previously reported LTP deficits observed
in slices of TS mice (Costa and Grybko,
2005) and demonstrate that chronic treat-
ment with this selective GABAA 5 NAM
can completely rescue LTP in TS mice.
RO4938581 rescued deficient
neurogenesis and normalized the
density of GABAergic synapse markers
in the hippocampus of TSmice
Because impairment in hippocampal cell proliferation and neu-
rogenesis is a major pathological hallmark in DS and TSmice, we
first assessed whether cell proliferation in the DG was affected by
chronic treatment of RO4938581 in TS and CO mice. We used
Ki67 immunohistochemistry to estimate the total number of the
actively dividing cells and confirmed the reduced number of
Ki67-positive cells in theDGof vehicle-treatedTS comparedwith
vehicle-treated COmice (p 0.024).We found that RO4938581
treatment completely restored the number of Ki67-positive cells
in the DG of TS mice and produced a less pronounced enhance-
ment in the density of this cell population inCOmice (p 0.033;
Fig. 3). In addition, neuronal survival of the cells that have un-
dergonematuration was also normalized in TSmice, as shown by
the increase in DAPI-positive cells found in TS hippocampus
after chronic RO4938581 administration (p  0.045; Fig. 4).
There was no significant increase in DAPI-positive cells in
RO4938581-treated CO mice.
Next, we used GAD65, GAD67, and VGAT/gephyrin immu-
nostainings to evaluate whether RO4938581 chronic treatment
affected the density of GABAergic synapse markers in the hip-
pocampus of TS and COmice.We found increased percentage of
area occupied by GAD65-, GAD67-, VGAT-, and VGAT/
gephyrin-positive boutons in the inner molecular layer of the
hippocampal DG of vehicle-treated TS mice compared with
vehicle-treated CO mice (p  0.001, p  0.001, p  0.001, and
p  0.013 respectively; Fig. 5). After chronic treatment with
RO4938581, the percentage of area occupied by GAD65-,
GAD67-, VGAT-, andVGAT/gephyrin-positive boutons was sig-
nificantly decreased in the hippocampus of TS mice similar to
that observed in vehicle-treated CO mice (p 0.017, p 0.016,
p 0.019, and 0.008 respectively; Fig. 5). RO4938581 treatment
produced a nonsignificant tendency to increase the number of
GAD65-positive boutons in CO mice (p  0.24). These results
indicate that negative modulation at GABAA 5 receptors by
RO4938581 can restore both deficient neurogenesis and en-
hanced density of GABAergic synapse markers in the hippocam-
pus of TS mice.
RO4938581 improved TSmice attention and did not affect
spontaneous activity or motor coordination
In the hole board, TS mice, under both treatments, performed a
larger number of crossings thanCOmice (p 0.001; Table 1). TS
mice showed altered attention because they repeated a larger
number of times the exploration of recently explored holes (A–
B–A index, p  0.021). After RO4938581 treatment, TS mice
A–B–A index was normalized. RO4938581 reduced this activity
in mice of both genotypes but this reduction did not reach statis-
tical significance (p 0.057). TS mice also showed a nonsignifi-
cant increased number of explorations (p  0.063) that was
reduced after RO4938581 (p 0.068). No significant differences
were found between mice of both genotypes and treatments in
the time they spent exploring the holes.
RO4938581 did not modify any of the sensorimotor abilities
tested in neither TS nor CO mice (vision, audition, strength, equi-
librium prehensile reflex, traction capacity, or motor coordination
in the coat-hanging test). Table 2 shows the score of RO4938581-
and vehicle-treated TS and CO mice in the different sensorimotor
methods; motor coordination in the rotarod was not affected by
genotype or treatment. TS and COmice presented a similar latency
to fall fromtherotarodatdifferent constant speeds.Furthermore,no
differenceswere foundbetweenRO4938581- andvehicle-treatedTS
Figure 2. RO4938581 rescued LTP in TSmice. Time courses of the initial slope of fEPSPs recorded from the apical dendritic layer
of the CA1 region in hippocampal slices after stimulation of the Schaffer collateral– commissural pathway at 30 s intervals. After 20
min of stable baseline recording, a theta burst stimulus induced robust LTP in hippocampal slices of vehicle-treated CO but not TS
mice. Long-term treatmentwith RO4938581 resulted in enhanced LTP that reached statistical significance in slices of TS but not CO
mice. The traces on top are superimposed, representative fEPSPs recorded before issuing the stimulus and at 60 min after stimu-
lation for each genotype. Calibration: 10ms, 1.0 mV. Data are presented as means SEM from vehicle-treated CO (n 11 slices
from 11different mice), vehicle-treated TS (n 12 slices from 12 different mice), RO4938581-treated CO (n 9 slices from 9
different mice), and RO4938581-treated TS (n 10 slices from 10 different mice) mice, respectively (for statistics, see Table 4).
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or COmice in the latency to fall at the different constant speeds. TS
andCOmice under both treatments did not differ in the amount of
spontaneous activity performed in their home cage during the dark
or the light phase of the cycle.
RO4938581 reduced hyperactivity without inducing anxiety-
like behavior or convulsions in TS mice
In the open-field test (Fig. 6), both mouse genotypes exhibited
similar activity asmeasured by crossing in themaze center. How-
ever, in the peripheral part of the open field, vehicle-treated TS
mice showed higher activity than CO mice (p  0.002), which
accounted for the increased total activity shown by TS mice
(p 0.001). RO4938581 increased the number of crossings per-
formed by CO mice in the center of the open field (p  0.045).
Because lower activity in the center of the open field is considered
an index of anxiety, an increase in the number of crossings per-
formed by COmice after RO4938581 treatment suggests that this
compound might have mild anxiolytic properties. RO4938581
did not affect general activity in TS and CO mice as indicated by
their similar horizontal total number of crossings (p 0.20) and
vertical activity (p 0.096; data not shown).
In the plus maze, TS mice were hyperactive because they per-
formed a larger number of entries in the open and closed arms
and total number of entries (p 0.005; Fig. 7a). Chronic admin-
istration of RO4938581 did not affect activity in this procedure
Figure 3. RO4938581 rescued neuronal proliferation in the hippocampus of TS mice. a,
Representative microscope images of coimmunostaining of DAPI (labeling all cell nuclei) and
Ki-67 (proliferating cells) in the DG region of hippocampus of vehicle- and RO4938581-treated
TS and COmice. Arrowheads indicate Ki-67-positive cells. Scale bar, 50m.b,Means SEMof
the density of Ki67-positive cells in vehicle- and RO4938581-treated TS and CO mice. **p
0.01 TS versus CO; #p 0.05, ##p 0.01 vehicle- versus RO4938581-treated mice; Bonferro-
ni’s tests after significant ANOVAs.
Figure 4. RO4938581 rescued granular cell density in the hippocampus of TS mice. a, Rep-
resentative microscope images of DAPI immunostaining in the GCL of the hippocampal DG of
vehicle- and RO4938581-treated TS and CO mice. Scale bar, 5 m. b, Means SEM of the
density of DAPI-positive cells in the GCL of vehicle- and RO4938581-treated TS and COmice (a).
#p0.05vehicle- versusRO4938581-treatedmice; Bonferroni’s tests after significantANOVAs.
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(p 0.066). Statistical analysis revealed that RO4938581 did not
affect the motor components of anxiety because TS and COmice
under the different treatment conditions did not differ in the
time freezing at the start of the test (p  0.17; Fig. 7b) or in the
percentage of time spent in the open arms (p  0.93; Fig. 7c).
However, RO4938581 reduced the cognitive components of anx-
iety as indicated by the lower number of risk assessment behav-
iors performed by TS andCOmice under chronic treatment with
this compound (p 0.017; Fig. 7d).
We demonstrated previously that RO4938581 lacked convul-
sant and proconvulsant activity after an auditory stimulus in the
DBA/2J mice. In the current study, we tested the convulsant po-
tential of RO4938581 inTSmice after a single oral administration
of 50mg/kg. RO4938581 did not induce convulsions in any of the
16 (eight TS and eight CO) mice tested at mean plasma concen-
trations of 3720 ng/ml. These plasma exposures were 2- to 3.3-
fold higher than the exposures achieved in animals during
chronic treatment.
Figure5. RO4938581 normalized the density of GABAergic synapsemarkers in the hippocampus of TSmice.a, Representative confocalmicroscope images of GAD65, GAD67, VGAT, and gephyrin
immunostaining in the innermolecular layer of the hippocampal DG, lining themost external layer of granule neuron in theGCL of vehicle- andRO4938581-treated TS and COmice.b,Means SEM
of thepercentageareaoccupiedbyGAD65-,GAD67-, VGAT-, andgephyrin-positiveboutons in thehippocampusof vehicle- andRO4938581-treatedTSandCOmice. *p0.05, **p0.01, TS versus
CO; #p 0.05, ##p 0.01, vehicle- versus RO4938581-treated mice; Bonferroni’s tests after significant ANOVAs.
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RO4938581 inhibited in vivo binding of [3H]RO0154513
similarly in TS and COmice
Autoradiographical analysis performed after intravenous injec-
tion of the GABAA 5 subtype preferring radioligand
[3H]RO0154513 showed comparable radioligand binding inten-
sities in TS and CO mice, suggesting similar expression levels of
GABAA 5 subunit-containing receptors in both mouse geno-
types (Fig. 8a, top row). Furthermore, the overall pattern of ra-
dioligand binding in the mouse brain was unchanged in both
strains and in good agreement with the known distribution of the
GABAA 5 receptor subunit. Strongest staining was observed in
brain regions known to contain high densities ofGABAA5, such
as the hippocampus and frontal cortex, whereas regions known
to contain less GABAA 5, such as the striatum and cerebellum,
showed lower accumulation of [3H]RO0154513.
The degree of GABAA 5 occupancy by a dose of 20 mg/kg
RO4938581 was estimated by evaluating the ability of the drug to
block the in vivo binding of [3H]RO0154513. In both TS and CO
mice, RO4938581 strongly reduced [3H]RO0154513 signals in
hippocampus and frontal cortex (Fig. 8a, bottom row). Plasma
and brain exposure of 20 mg/kg RO4938581 was found to be
similar in both genotypes (mean plasma exposure, 1311 and 1395
ng/ml and mean brain exposure, 905 and 995 ng/ml for CO and
TS, respectively). Inhibition of radioligand binding by 20 mg/kg
RO4938581 in the hippocampus of TS and CO mice was esti-
mated using the hippocampus/cerebellum ratio of radioligand
accumulation as an indication of specific
radioligand binding. Pretreatment of TS
and CO mice with RO4938581 decreased
specific binding of [3H]RO0154513 in the
hippocampus by 72 and 68%, respectively
(Fig. 8b).
Discussion
These results demonstrate that selectively
inhibiting the effect of GABA at GABAA
5 receptors can reverse concomitantly
electrophysiological, morphological, and
cognitive deficits of TSmice. In this study,
we showed that chronic administration of
a GABAA 5 NAM, RO4938581, rescued
cognitionandbehavioral deficits in adultTS
mice without inducing anxiety, convul-
sions, or overtmotor effects. In addition,we
showed that, in the hippocampus of chron-
ically treated TS mice, RO4938581 rescued
the deficits in LTP, adult neurogenesis, and
normalized the density of GABAergic syn-
apse markers.
In agreement with previous studies
(Escorihuela et al., 1995; Holtzman et al.,
1996; Rueda et al., 2008a), TS mice had a
pronounced learning deficit in the acqui-
sition sessions of the visible and hidden
platform task as well as in the probe trial
of the Morris water maze. Chronic
treatment with RO4938581 significantly
improved TS mice performance in the
acquisition sessions, probe trial, and
cued sessions, indicating rescue of spatial
learning and memory. In addition, vehicle-
treated TS mice displayed enhanced thig-
motaxis; RO4938581 reduced this behavior
inTS andCOmice in the hidden and visible
platform tasks of themaze, indicating that drug treatment improved
navigation strategies. These results are in agreement with those by
Braudeau et al. (2011) who also reported an improvement in spatial
learning and navigation strategies in the Morris water maze with
another functionally selective GABAA 5 NAM.
Figure 6. RO4938581 administration did not induce anxiety in the open field. Data are
expressed as mean SEM of the number of crossings performed by RO4938581- and vehicle-
treated TS and CO mice in the center, periphery and of total activity in the open field. **p
0.01, TS versus CO; #p 0.05, RO498581 versus vehicle; Bonferroni’s tests after significant
ANOVAs (for statistics, see Table 5).
Figure7. RO4938581 administration reducedhyperactivity of TSmicewithout inducing anxiety-like behavior in the plusmaze.
Data are expressed asmean SEMof the number of entries in the open and closed arms andnumber of total entries (a), the initial
freezing time (b), the percentage of time spent in the open arms (c), and the number of risk assessment behaviors (d) in the plus
maze. *p 0.05, **p 0.01, CO versus TS; #p 0.05, RO498581 versus vehicle; Bonferroni’s tests after significant ANOVAs (for
statistics, see Table 5).
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Enhanced thigmotactic behavior of TS
mice and their poor performance in the
cued test could be related to a profound
disruption in procedural learning thatwas
subsequently ameliorated by RO4938581
treatment. It is possible that TS mice have
an impaired ability to inhibit an inadequate
learning strategy that probably is responsi-
ble for the enhanced escape latencies in the
water maze. There is evidence that the visi-
ble platform task also requires different pro-
cedural learning abilities (Whishaw and
Mittleman, 1986; Fenton and Bures, 1993).
Procedural learning is dependent on striatal
function, and it has been shown that the in-
trastriatal cholinergic system is functionally
altered in TSmice (Di Filippo et al., 2010).
In this study, vehicle-treated CO mice
performed well in both the acquisition
sections and probe trial of the watermaze:
there was no difference in performance be-
tween RO4938581- and vehicle-treated CO
mice. This could have been attributable to a
“ceiling effect” that resulted in the inability
to detect additional improvement in learn-
ing andmemory after drug treatment in the
mice. Alternatively GABAA 5 NAMs may
have a selective effect on memory under
conditions in which there is excessive
inhibition.
Hippocampal-mediated cognitive pro-
cesses involve long-termchanges in synaptic
efficacy, such as LTP. Several studies have
reported that there is deficient LTP in
the hippocampus of TS mice that was
pharmacologically rescued by blocking
either GABAA or GABAB receptors
(Kleschevnikovetal.,2004;CostaandGrybko,
2005; Fernandez et al., 2007; Kleschevnikov
et al., 2012). In the present study, a more
physiologic, theta burst stimulus was used
to induce LTP in the CA1 region of the hippocampus. TS mice had
an LTP deficit, similar to that reported previously by Costa and
Grybko (2005).Chronic treatmentwithRO4938581completely res-
cued the LTP deficit of TS mice and also tended to enhance the
induction of LTP in CO mice. Previous studies showed that
RO4938581 and other GABAA 5 NAMs enhanced LTP after acute
treatment in mouse hippocampal slices (Collinson et al., 2006;
Dawson et al., 2006; Ballard et al., 2009). GABAA 5 receptors, pre-
dominantly localized extrasynaptically, mediate tonic inhibition
(Glykys et al., 2008) and regulate the excitability of hippocampal
pyramidal neurons by influencing the strength of depolarization re-
quired to generate an action potential (Bonin et al., 2007). Our re-
sults provide additional evidence for a major role of GABAA 5
receptors in the modulation of long-term synaptic plasticity and
suggest that this may be a mechanism whereby RO4938581 treat-
ment rescues cognitive deficits in TSmice.
In TS mice, deficits in hippocampus-dependent learning and
synaptic plasticity have been linked to enhanced inhibition, and
these functional deficits seem to correlate with alterations in hip-
pocampal morphology, such as reductions in granule cell density
and hippocampal neurogenesis (Insausti et al., 1998; Rueda et al.,
2005; Clark et al., 2006; Lorenzi and Reeves, 2006; Bianchi et al.,
2010; Llorens-Martín et al., 2010). In agreement with those stud-
ies, we found hippocampal neurogenesis and the number of ma-
ture granule cells reduced in TS mice. Importantly, chronic
administration of RO4938581 fully restored both the density of
proliferating cells and the number of mature granule cells in the
GCL of TS mice. These results suggest that chronic treatment
with RO4938581 can restore cell proliferation and survival of
neurons that have undergone maturation in TS mouse hip-
pocampus probably as a consequence of restoring deficient LTP.
Indeed, synaptic plasticity within a cellular network of mature
hippocampal neurons has been shown to promote neuronal dif-
ferentiation of newly generated cells (Babu et al., 2009). In addi-
tion, GABAA receptor activity has been shown to regulate
neuronal proliferation, migration, differentiation, and integra-
tion of newly generated neurons (Tozuka et al., 2005; Ge et al.,
2006; Earnheart et al., 2007; Song et al., 2012). Because both
newborn andmature neurons seem implicated in hippocampus-
dependent learning andmemory, the restoration of proliferation
and the density of mature neurons is likely to be involved in the
cognitive-enhancing effects of RO4938581 in TS mice. A recent
study showed that restoring neurogenesis with fluoxetine im-
proved cognitive performance in TS mice (Bianchi et al., 2010).
Figure 8. Inhibition of [ 3H]RO0154513 in vivo binding by RO4938581 (20 mg/kg) in TS and COmice. a, Representative ex vivo
autoradiographical images of sagittal brain sections of CO and TS mice injected with [ 3H]RO0154513 and pretreated with vehicle
or RO4938581.b, Inhibition of specific radioligand binding by RO4938581 (20mg/kg) in the hippocampus of CO and TSmice. Data
are expressed as the hippocampus/cerebellum ratio of radioligand binding assuming that binding in the cerebellum is mainly
nonspecific.
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In line with enhancedGABA-mediated inhibition observed in
TSmice, we found an increased density of theGABAergic synapse
markersGAD65,GAD67, andVGAT in themolecular layer of the
hippocampus of TS mice that was normalized by chronic
RO4938581 administration. Increased immunoreactivity of pro-
teins associated with GABAergic synapses, including GAD67,
VGAT, GABAA receptor-associated protein, and neuroligin 2,
had been measured previously in the neocortex and hippocam-
pus of TS mice (Belichenko et al., 2009; Pe´rez-Cremades et al.,
2010). Because numerous studies have shown that TS mice dis-
play morphological and functional alterations in inhibitory cir-
cuitries in the hippocampus and cerebral cortex (Belichenko et
al., 2004, 2009; Chakrabarti et al., 2010; Pe´rez-Cremades et al.,
2010; Begenisic et al., 2011), it is possible that RO4938581 res-
cued cognitive deficits inTSmice by normalizing the number and
function of inhibitory synapses and, therefore, reestablished cir-
cuit inhibitory/excitatory balance and neuroplasticity. In addi-
tion, our results suggest that drug treatment in normal animals
might induce compensatory mechanisms to maintain circuit in-
hibitory/excitatory balance in the CNS.
Consistent with previous reports (Escorihuela et al., 1995;
Coussons-Read and Crnic, 1996), we also found TS mice hyper-
active in the open field, plus maze, and hole-board procedures.
Chronic treatment with RO4938581 suppressed hyperactivity in
the plusmaze and hole board but not in the open field. It has been
proposed that the hyperactivity of TSmice in situations that usually
provoke caution and suppress activity in normal mice (Escorihuela
et al., 1995; Coussons-Read and Crnic, 1996; Martínez-Cue´ et al.,
2006) is attributable to reduced attention to potentially dangerous
stimuli (Crnic and Pennington, 2000). Interestingly, RO4938581
also rescued theattentiondeficits found inTSmice in thehole-board
method.
Importantly, RO4938581 did not induce anxiety-like behav-
ior in the open field and plus maze. On the contrary, chronic
treatment with this compound had an anti-anxiety-like effect
because it increased the number of crossings performed by CO
mice in the center of the open field. In the plus maze, although
RO4938581 did not affect the motor components of anxiety, it
reduced a cognitive component of anxiety as indicated by the
lower number of risk assessment behaviors performed by chron-
ically treated TS and CO mice. In addition, RO4938581 did not
induce convulsions in TS or CO mice after chronic treatment or
when administered at a dose higher than that used in the chronic
study. RO4938581 did notmodifymotor ability, coordination, or
amount of spontaneous activity in TS or CO mice. These results
further confirm a previous report (Ballard et al., 2009) that
showed that RO4938581 did not induce several relevant CNS side
effects. In agreement with data on 5IA, a functionally selective
GABAA 5 NAM (Braudeau et al., 2011), our results support the
notion that GABAA5 receptorsmay be appropriate drug targets
for improving cognition in DS without the unwanted side effects
associated with activity at other GABAA receptor subtypes.
In vivo binding experiments using [3H]RO0154513 demon-
strated similar density and distribution ofGABAA5 receptors in
TS andCOmice that is in agreement withmRNA expression data
(Vink et al., 2009). Also, similar levels of receptor occupancywere
observed in the hippocampus of RO4938581-treated TS and CO
mice. Treatment with RO4938581 (20mg/kg, p.o.) decreased the
hippocampal binding of [3H]RO0154513 in both genotypes by
70%. These data suggest that occupancy and negative modula-
tion of 70% of hippocampal GABAA 5 receptors is required
for the observed pharmacological effect of RO4938581 in TS
mice. Together, these results provide evidence for the potential
therapeutic use of selective GABAA 5 NAMs to treat cognitive
deficits in individuals with DS.
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